Novartis cancer med combats lymphoma

The Novartis kidney-cancer remedy Afinitor cut tumor size by 50 percent or more in a third of lymphoma patients in a mid-stage trial; the Swiss drugmaker has started a late-stage trial to evaluate disease-free survival in patients with that disease. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.